Systemischer Lupus erythematodes

Schlüsselwörter

CME - Rheumatologie

Literatur

• 1 Borba E F, Bonfa E. Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy.  J Rheumatol. 2001;  28 780-785
• 2 Boumpas D T, Austin H A, Vaughan E M. et al . Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis.  Lancet. 1992;  340 741-745
• 3 Cervera R, Khamashta M, Font J. et al . Systemic Lupus Erythematosus: Clinical and Immunologic Patterns of Disease Expression in a Cohort of 1,000 Patients.  Medicine. 1993;  72 113-124
• 4 Chan T F. et al . Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus nehritis.  N Engl J Med. 2000;  343 1156-1162
• 5 DiFino S M, Lachant N A, Kirshner J J, Gottheb A J. Adult idiopathic thrombocytopenic purpura: Clinical findings and response to therapy.  Am J Med. 1980;  69 430
• 6 Fauci A S. Immunosuppressive and anti-inflammatory effects of glucocorticoids. Springer Verlag, New York In: Baxter JD, Rousseau GG (eds): Glucocorticoid Hormone Action 1979
• 7 Fischer-Betz R, Specker C. Antiphospholipid-Antikörper und Schwangerschaft.  Akt Rheumatol. 2003;  28 131-137
• 8 Gladman D D, Urowitz M B, Rahman P. et al . Accrual of organ damage over time in patients with systemic lupus erythematosus.  J Rheumatol. 2003;  30 1955-1959
• 9 Hochberg M C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.  Arthritis Rheum. 1997;  40 1725
• 10 Houssiau F A, Vasconcelos C, D’Cruz D. et al . Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.  Arthritis Rheum. 2002;  46 2121-2131
• 11 Khamastha M A. Hughes Syndrome, Antiphospholipid Syndrome. Springer Verlag London 2000
• 12 Manzi S, Selzer F, Sutton-Tyrrell K. et al . Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus.  Arthritis Rheum. 1999;  42 51-60
• 13 Meroni P L, Moia M, Derksen R H. et al . Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxis.  Lupus. 2003;  12 504-507
• 14 Ostendorf B, Scherer A, Specker C, Modder U, Schneider M. Jaccoud’s arthropathy in systemic lupus erythematosus: differentiation of deforming and erosive patterns by magnetic resonance imaging.  Arthritis Rheum. 2003;  48 157-165
• 15 Petri M, Perez-Gutthann S, Spence D, Hochberg M C. Risk factors for coronary artery disease in patients with systemic lupus erythematosus.  Am J Med. 1992;  93 513-519
• 16 Petri M. Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update.  Arthritis Care Res. 1995;  8 137-145
• 17 Sato E I. Methotrexate therapy in systemic lupus erythematosus.  Lupus. 2001;  10 162-164
• 18 Tan E M, Cohen A S, Fries J F. et al . The 1982 revised criteria for the classification of systemic lupus erythematosus.  Arthritis Rheum. 1982;  25 1271-1277
• 19 Tsakonas E, Joseph L, Esdaile J M. et al . A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group.  Lupus. 1998;  7 80-85
• 20 Uramoto K M, Michet C J, Thumboo J. et al . Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992.  Arthritis Rheum. 1999;  42 46-50
• 21 Urowitz M B, Gladman D D. Evolving spectrum of mortality and morbidity in SLE.  Lupus. 1999;  8 253-255
• 22 Weening J J, D’Agati V D, Schwartz M M. et al . The classification of glomerulonephritis in systemic lupus erythematosus revisited.  Kidney Int. 2004;  65 521-530
• 23 Wenzel J, Tüting T, Bieber T. Kutane Manifestationen des Lupus erythematodes.  Dtsch Med Wochenschr. 2003;  128 1655-1658